Antitumour Activity of DWA2114R in Mice with Leukaemia
Author Information
Author(s): K. Akamatsu, K. Endo, T. Matsumoto, K. Kamisango, K. Morikawa, M. Koizumi, K. Koizumi
Primary Institution: Exploratory Research Laboratories, Chugai Pharmaceutical Co. Ltd., Gotemba, Japan
Hypothesis
The study investigates the time dependency of the antitumour activity of DWA2114R against advanced L1210 leukaemia in mice.
Conclusion
DWA2114R shows superior antitumour activity against advanced L1210 leukaemia when administered at a specific time point.
Supporting Evidence
- DWA2114R showed a significant increase in survival time when administered on day 6 after inoculation.
- The antitumour activity of DWA2114R was not observed in athymic nude mice, indicating the role of T cells.
- Mice treated with DWA2114R on day 6 had a drastic reduction in ascites tumour cells.
Takeaway
This study found that a new drug, DWA2114R, works better against a type of cancer in mice when given at a certain time after the cancer starts.
Methodology
Mice were inoculated with L1210 leukaemia cells and treated with DWA2114R at different time points to evaluate its antitumour activity.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Male 6-week-old DBA/2 and BALB/c mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website